Oxford BioDynamics Plc (AIM: OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship product, EpiSwitch CiRT, predicts how a patient will respond to immune checkpoint inhibitor therapies. OBD's proprietary EpiSwitch® platform harnesses 3D genomic regulation biomarkers to develop molecular diagnostic classifiers for numerous indications, including predicting response to therapy, patient prognosis, disease diagnosis, and residual disease monitoring.
Answer ALS is the single largest & most comprehensive ALS research project in history, producing more ALS data than has ever been amassed, while openly sharing with the global research community. The program coordinates with over 20 institutions, establishing a critical foundation for new clinical trials and developing new ways to categorize ALS patients to identify specific druggable pathways in an effort to make ALS a treatable disease. Since opening the Answer ALS data repository, Neuromine, in 2021, over 300 independent ALS research projects have begun worldwide from free access to the rich data and available samples.
bit.bio combines the concepts of coding and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines. Our precision cell programming technology opti-oxTM enables deterministic activation of TF codes to program new cell identities including neurodegenerative disorders such as Gaucher’s, Huntington’s and Parkinson’s disease. opti-ox reprogramming overcomes the ultimate barriers of cell manufacturing and enables precise, rapid and scalable generation of pure human cell types.
PRC Clinical is the CRO of choice for ALS trials, providing specialty CRO services for over 20 years. Our innovative approach to executing studies combines cutting-edge technology with extensive experience and deep therapeutic knowledge. PRC Clinical delivers strategic solutions and high-touch approaches that ensure patients get the support they need to remain engaged and enrolled throughout your trial. Along with our host of online management tools, we ensure your trial receives the TLC it deserves from PRC.
Neuro-Sys, founded in 2013 in France, is a leading research firm specializing in pharmacology, with a strong focus on in vitro and in vivo studies for neurodegenerative diseases affecting the Central and Peripheral Nervous Systems. To meet the growing need for specialized contract research services, it offers efficacy studies notably based on primary cell culture models. Our expertise in pharmacological agents and biomolecular analysis enhance the understanding of the mode of action of client’s compounds.
For in vivo studies, Neuro-Sys employs sophisticated techniques such as stereotaxic injections to deliver substances directly into specific brain areas, behavioral analysis to assess the effects of treatments on cognition and motor functions, and histology to examine the detailed structure of tissues post-treatment. This comprehensive approach allows for a deeper insight into disease pathology and the efficacy of potential therapies.
The company's reputation is built on its team of highly experienced neuropharmacologists, physicians, and neurologists, each with over twenty years of industry experience. By investing in research and development and utilizing the latest technologies and customized automated platforms, Neuro-Sys delivers high-quality, reliable results. This commitment enhances service efficiency and strengthens the trust of its partners.
Atlantic Research Group
ARG is a contract research organization focused on oncology, immunology, and neurology, providing comprehensive clinical program development services ranging from planning to commercialization, achieving over 50 market authorizations to date. Founded in 2004 with the vision that every project should be highly individualized, ARG has experienced consistent growth across the globe, expanding our range to include drug and device strategic consulting, clinical trial management services, as well as clinical data and analytic solutions. ARG uses first-in-class technology platforms along with relationship-driven flexibility to optimize clinical studies because we believe everyone deserves to be well.
With more than 35 products launched in over 60 countries, the Zydis® ODT (orally disintegrating tablet) fast-dissolve technology continues to be the world’s best-in-class ODT technology. The Zydis fast-dissolve platform consists of three technologies: Zydis ODT, Zydis Ultra, and Zydis Bio. Zydis ODT is a unique freeze-dried dosage form that disperses within three seconds without the need for water. Zydis Ultra technology offers enhanced taste-masking capabilities, increased drug loading, and the potential for functional coating. Zydis Bio technology offers a formulation strategy for oral delivery of peptides, allergens, and viral vaccines.
PsychoGenics is a preclinical CRO with expertise in CNS and orphan disorders. Our mission is to provide the best validated disease models and comprehensive preclinical capabilities to help companies discover the next generation of treatments and reduce the attrition rate in clinical development. Our capabilities include behavioral testing, surgical models, electrophysiology, translational EEG, quantitative histology, biomarker analysis, bioanalysis and microdialysis. We offer a variety of validated mouse models including in-licensed transgenic models that support research in areas such as amyotrophic lateral sclerosis, Alzheimer's disease, Huntington’s disease, Parkinson’s disease, autism spectrum disorders, psychosis and schizophrenia, spinal muscular atrophy, muscular dystrophy and a broad array of pain models.
Unlearn is a San Francisco-based technology company pioneering generative machine learning methods to eliminate trial and error in medicine. Unlearn’s technology using patient digital twins is regulatory-qualified and used by leading global pharmaceutical companies to run AI-powered clinical trials that reach full enrollment faster and bring new treatments to patients sooner.